Tekmira Official Defends apoB as Cholesterol Target, Touts RNAi Rx Over Isis Antisense Candidate | GenomeWeb

By Doug Macron

Tekmira Pharmaceuticals President and CEO Mark Murray this week defended his company's selection of apolipoprotein B as the target in its phase I hypercholesterolemia program, calling it "well validated" in light of clinical data generated by Isis Pharmaceuticals with its apoB-targeting antisense drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.